Preliminary results on the postmortem measurement of 3-beta-hydroxybutyrate in liver homogenates. by Palmiere, C. et al.
ORIGINAL ARTICLE
Preliminary results on the postmortem measurement
of 3-beta-hydroxybutyrate in liver homogenates
Cristian Palmiere & Patrice Mangin & Dominique Werner
Received: 18 December 2012 /Accepted: 6 May 2013 /Published online: 31 May 2013
# Springer-Verlag Berlin Heidelberg 2013
Abstract The concentrations of 3-beta-hydroxybutyrate
(3HB) in blood and two liver samples were retrospectively
examined in a series of medicolegal autopsies. These cases
included diabetic ketoacidosis, nondiabetic individuals
presenting moderate to severe decompositional changes
and nondiabetic medicolegal cases privy of decompositional
changes. 3HB concentrations in liver sample homogenates
correlate well with blood values in all examined groups.
Additionally, decompositional changes were not associated
with increases in blood and liver 3HB levels. These results
suggest that 3HB can be reliably measured in liver homog-
enates when blood is not available at autopsy. Furthermore,
they suggest that metabolic disturbances potentially leading
or contributing to death may be objectified through liver
3HB determination even in decomposed bodies.
Keywords Postmortem biochemistry . 3-Beta-
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Introduction
Specific molecules may prove much more difficult to iden-
tify in biological samples collected during autopsy com-
pared to clinically derived specimens. Indeed, the presence
of compounds generated by putrefaction and the often-
altered (decomposed) nature of the samples limit the direct
applicability of clinically validated assays in a postmortem
setting [1]. While peripheral blood, urine, and gastric contents
represent the ideal biological fluids for toxicological purposes,
they may be partly or completely unavailable in infant autop-
sies and severely decomposed corpses. Furthermore, should
body damage in cases such as traffic accidents, fire fatalities,
and explosions be extensive, the collection of sufficient
amounts of blood, urine, and other samples for toxicology
and biochemistry would be consequently limited.
Significant effort has therefore been directed towards
identifying alternative, liquid or solid, biological specimens
for toxicological analyses. Alternatives considered include
liver, kidney, skeletal muscle, brain, lung, adipose tissue,
and bone marrow samples as well as possible larvae of
insects feeding on the host [1, 2].
Postmortem biochemical analyses are routinely performed
on vitreous humor (glucose and electrolytes), whole blood
(glycated hemoglobin and ketones) and postmortem serum
obtained from peripheral or cardiac blood (markers of hepatic,
cardiac and renal functions, various hormones, tryptase,
markers of inflammation, and sepsis). Urine, pericardial, ce-
rebrospinal, and synovial fluids are occasionally used for
chemical and biochemical investigations. However, blood
and urine samples collected during autopsy are usually re-
served for toxicological analyses. Vitreous humor, pericardial,
synovial, and cerebrospinal fluids are not systematically sam-
pled. Additionally, their use is rather episodic and usually
limited to situations in which blood and urine are unavailable.
As far as toxicology is concerned, the nature of the biolog-
ical fluids collected from putrefied bodies may significantly
reduce their application possibilities, rendering the direct ap-
plication of clinically validated methods to decomposed sam-
ples for biochemical purposes impracticable.
Over the last 20 years, there has been a growing interest
in the development of methods for qualitative and quantita-
tive analysis of several compounds in postmortem matrices
alternative to blood, despite the existence of objective limits
related to sample handling and processing.
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These difficulties are mainly due to decompositional
changes, postmortem autolysis, bacterial contamination, tis-
sue homogenization, challenges in obtaining representative
samples, time consuming techniques, as well as analytical
and chromatographic obstacles. The analytical methods
must therefore be able to minimize the role of potentially
interfering substances such as lipids, proteins, and numerous
other molecules which are usually present in high concen-
trations in such matrices [3–6].
Tissue samples obtained from the liver and kidney
are often used in postmortem toxicology analysis, espe-
cially when blood is unavailable. Kidney and liver tis-
sues are suitable to prepare homogenates; yet, as already
mentioned, they also contain high concentrations of
lipids, which may interfere with the analytical proce-
dures’ performance.
As a specimen, liver has the advantage of being
relatively unaffected by postmortem redistribution com-
pared to blood, although drug concentrations in its left
side, which is proximal to the stomach and small intes-
tine, may be affected by the postmortem diffusion of
some compounds. Since most drugs are metabolized in
the liver, both the parent substance and its metabolites
may be present in high concentrations in the hepatic
tissue. Additionally, one of the main problems in using
liver samples for forensic purposes is the lack of a
database concerning the hepatic concentrations of most
analyzed molecules. The results obtained from liver
analysis are therefore more complicated to interpret [7].
In the realm of postmortem biochemistry, C-reactive
protein (CRP) has mainly been determined in postmortem
serum from femoral blood. It has, however, been experi-
mentally measured in other biological matrices, such as
pericardial fluid, vitreous humor, cerebrospinal fluid, and
liver homogenates, at times with promising results [8].
Astrup and Thomsen [9] investigated CRP levels in 50
forensic autopsy cases in different specimens, including
liver samples, and concluded that liver CRP levels correlate
well with postmortem serum concentrations, suggesting the
possibility of using liver samples for CRP determination
should blood or postmortem serum prove unavailable.
Apart from this example, liver homogenates have not been
used further for postmortem biochemical purposes.
The aim of this study was to investigate 3-beta-
hydroxybutyrate (3HB) levels in blood and liver sam-
ples in a series of medicolegal autopsies that included
cases of diabetic ketoacidosis and bodies presenting
decompositional changes. The intention was to charac-
terize 3HB concentrations in liver homogenates in
comparison to blood levels as well as evaluate the
usefulness of 3HB determination in liver samples in
order to assess the metabolic disturbances potentially
leading or contributing to death.
Material and methods
Forensic autopsy cases
A total of 48 subjects (28 males and 20 females) were
included in this study and retrospectively selected from
2008 to 2012. Subject age range was between 16 and
78 years old, with a mean age of 54.6 years. All cases
included in the study underwent complete autopsies
preceded by unenhanced CT scans. Autopsies were or-
dered by the public prosecutor due to unclear circum-
stances of death and the bodies were transferred to the
medicolegal center. Toxicology and histology were
performed in all cases included in this study despite
the presence of decompositional changes in most organs
in a portion of the selected cases. Medical records,
social histories of the deceased when available, as well
as police reports were reviewed in all cases before
conclusions were made.
The availability of both blood (peripheral or cardiac) and
liver samples at autopsy was the inclusion criterion for the
cases chosen.
The selected study population consisted of 7 diabetic
ketoacidosis cases without decompositional changes, 1
insulin-dependent diabetic individual presenting severe
decompositional changes, 20 nondiabetic cases (according
to medical records) presenting moderate to severe
decompositional changes, and 20 nondiabetic cases (according
to medical records) without decompositional changes.
Vitreous glucose concentrations were measured in all
cases where vitreous humor was collected during autopsy.
According to the literature [10], diabetic ketoacidosis
was determined to be the cause of death when vitreous
glucose concentrations were above 10 mmol/l (corre-
sponding to 104 mg/ml) and blood 3HB levels were
higher than 2.5 mmol/l (corresponding to 26 mg/ml), as
well as when other causes of death were excluded based on all
postmortem investigations. The insulin-dependent diabetic
individual with severe decompositional changes showed a
cardiac blood 3HB concentration consistent with the hypoth-
esis of ketoacidosis as the cause of death (9.6 mmol/l, corre-
sponding to 100 mg/ml). Vitreous humor was unavailable in
this case.
The causes of death in the 20 individuals presenting
moderate to severe decompositional changes were hangings
(two cases), gunshot wounds (two cases), drug intoxication
(three cases), drowning (two cases), natural deaths (six
cases), and unknown (five cases).
The causes of death in the 20 individuals without
decompositional changes were determined to be drug
intoxication (four cases), hangings (six cases), coronary
thrombosis (three cases), and ischemic heart disease
(seven cases).
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Blood samples
Peripheral blood samples were collected by aspiration with a
sterile needle and a syringe from the left or right femoral
vein(s) during autopsy. Blood samples were drawn after
clamping the vein(s) at the proximal end and lifting the
lower limb(s) for several minutes. Peripheral blood was
not available in 11 out of 20 cases with moderate to severe
decompositional changes as well as the insulin-dependent
diabetic individual presenting a high degree of decomposi-
tion. In these cases, blood was sampled from the right and
left cardiac cavities. Both peripheral and cardiac blood
samples were stored in tubes containing sodium fluoride
and immediately frozen at −20 °C.
Vitreous samples
Undiluted vitreous humor samples were obtained by aspira-
tion using a sterile needle and syringe as soon as possible
upon arrival of the bodies at the morgue. Right and left
vitreous samples were collected through a scleral puncture
at the lateral canthus, aspirated from the center of each eye,
pooled in the same syringe, and mixed together. After col-
lection, vitreous samples were immediately centrifuged at
3,000×g for 15 min. The separated supernatant was collect-
ed and stored in preservative-free tubes. Vitreous samples
were transferred to the laboratory immediately after having
performed the autopsies. When glucose determination was
delayed, vitreous samples were stored at −20 °C.
Liver samples
Two samples (A sample and B sample) were collected in
each case from the central part of the right lobe of the liver
during autopsy. The first set of samples (A samples) was
immediately homogenized using a laboratory blender. The
tissue specimens were cut into small pieces with a dispos-
able scalpel and 4 g was weighed out. Four milliliters of
sterile, sodium chloride solution 0.9 % was added to the
tissue (dilution 1:1). The second set of samples (B samples)
was stored in preservative-free tubes and frozen at −20 °C.
After 30 days, samples were thawed overnight at 4 ° C and
homogenized using the same protocol as was used with the
A samples. Complete homogenization of the tissue samples
was not always possible due to specimen quality. However,
approximately 90 % tissue homogenization was achieved by
using the laboratory blender for 4 min.
Laboratory assays
3HB concentrations were determined on a Cobas Mira Plus
(Roche Diagnostics, Switzerland) by an enzymatic photo-
metric method adapted in house from the technique
described by Ruell and Gass [11]. Frozen femoral and
cardiac blood samples were thawed overnight at 4 ° C and
deproteinized with perchloric acid. Supernatant was used for
analysis. Similarly, liver homogenates (samples A and B)
were deproteinized with perchloric acid and supernatant was
used for analysis. 3HB concentrations were expressed in
millimole per liter.
Glucose was determined on vitreous samples by enzy-
matic assays on a Dimension® Xpand® Plus Integrated
Chemistry System (Siemens Healthcare Diagnostics Inc.,
Deerfield, IL, USA). Glucose concentrations were
expressed in millimole per liter.
Statistical analysis
In diabetic ketoacidosis cases, in nondiabetic cases
presenting moderate to severe decompositional changes
and in nondiabetic cases privy of decompositional changes,
3HB concentrations in blood and liver samples were com-
pared by matched pair test. The comparisons between pa-
tient groups were carried out by using the Wilcoxon test.
The linear relationship between 3HB in blood and liver
samples was explored by Pearson’s product–moment test.
Correlation coefficient value ≥0.8 and between 0.7 and 0.79
was considered to define a very strong and strong correla-
tion between variables, respectively, while coefficient rang-
ing between 0.69 and 0.5 and 0.49 to 0.3 was considered to
define moderate and low correlation, respectively.
Ethical aspects
Ethical aspects were discussed with the local ethics commit-
tee. Since the medicolegal autopsies had been ordered by the
judicial authorities, analyses were performed as part of the
investigations and no further ethical permission was required.
Results
3HB concentrations in blood and liver samples as well as
the relative differences between values observed in A sam-
ple versus B sample and A sample versus blood in the three
studied groups are summarized in Table 1.
In cases of diabetic ketoacidosis, 3HB levels ranged from
6.70 to 21.50 mmol/l (corresponding to 69.80 and
223.95 mg/ml, respectively), from 6.60 to 20.50 mmol/l
(corresponding to 68.75 and 213.55 mg/ml, respectively),
and from 5.30 to 18.50 mmol/l (corresponding to 55.20 and
192.70 mg/ml, respectively) in blood, A samples and B
samples, respectively. Concentrations were statistically
higher in blood than A samples (mean difference 1.46;
95 % CI 0.84, 2.09; p value <0.001) and in A samples than
B samples (mean difference 0.78; 95 % CI −0.27, 1.28; p
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value=0.008). The relative differences between 3HB levels
in A samples versus B samples and A samples versus blood
were ≤21 % of A sample concentration in all cases of
diabetic ketoacidosis.
Similarly, in nondiabetic cases presenting moderate to
severe decompositional changes and in nondiabetic cases
privy of decompositional changes, 3HB concentrations were
statistically higher in blood than A samples (mean differ-
ence 0.01; 95 % CI 0.008, 0.01; p value <0.001 and mean
difference 0.0045; 95 % CI 0.0021, 0.0089; p value <0.001,
respectively) and in A samples than in B samples (mean
difference 0.009; 95 % CI 0.005, 0.012; p value <0.001 and
mean difference 0.002; 95 % CI 0.0001, 0.0039; p value=
0.042, respectively) (Table 1).
The relative differences between 3HB levels in A samples
versus B samples and A samples versus blood were ≤15
and ≤10 % of A sample concentration in all the nondiabetic
cases presenting decompositional changes and in all the
nondiabetic cases without decompositional changes,
respectively.
3HB concentrations were significantly higher in cases of
diabetic ketoacidosis than in the other studied groups in both
blood and liver samples (p<0.001 for every comparison).
3HB values were higher in nondiabetic cases presenting
moderate to severe decompositional changes than in
nondiabetic cases privy of decompositional changes in both
blood and liver samples (p<0.001 for every comparisons).
However, in all tested samples of both groups, 3HB con-
centrations were lower than the blood clinical reference
value (0.17 mmol/l, corresponding to 1.77 mg/ml).
Linear dependence between the three variables was
shown by Pearson’s product–moment coefficient in the
three groups (Table 2). Pearson’s product–moment coeffi-
cient was ≥0.9, p value<0.001, and R-square ≥0.84 in every
correlation between variables and in every group.
The linear function of 3HB levels in A samples versus B
samples and in A samples versus blood is reported in Table 3.
Slopes and intercept of the regression line equations were very
close to 1 and 0, respectively, and their values ±2 standard
error included 1 and 0 for every correlation (Table 3).
Table 1 3-Beta-hydroxybutyrate concentrations in blood and liver samples and relative difference between values observed in A samples versus B
samples and A samples versus blood in the three studied groups
Diabetic
ketoacidosis
Nondiabetic cases presenting moderate
to severe decompositional changes
Nondiabetic cases privy
of decompositional changes
Liver A Median 9.95 (103.65) 0.16 (1.67) 0.12 (1.25)
Range 6.60–20.50 0.10–0.17 0.10–0.16
(1.04–1.67) (68.75–213.55) (1.04–1.77)
Liver B Median 9.60 (100.00) 0.15 (1.56) 0.12 (1.25)
Range 5.30–18.50 0.10–0.16 0.10–0.16
(55.20–192.70) (1.04–1.67) (1.04–1.67)
Blood Median 11.90 (123.96) 0.17 (1.77) 0.13 (1.35)
Range 6.70–21.50 0.10–0.18 0.10–0.16
(69.80–223.95) (1.04–1.87) (1.04–1.67)
(liver A − liver B)/liver A Range 2.91 to 19.7 % 0 to 12.5 % 0 to 9.09 %
(liver A − blood)/liver A Range −21.05, −1.51 % −15.38 %, 0 −10 %, 0
3HB concentrations are expressed in millimole per liter and (milligram per deciliter)
Table 2 Correlation between
3HB in blood and liver samples
in the three studied groups
assessed by Pearson’s product–
moment coefficient test




trol nondiabetic cases without
decompositional changes
Group Variable by variable Pearson’s product–moment coefficient test
Correlation p value
DB Liver A vs blood 0.99 <0.001
Liver B vs blood 1 <0.001
Liver B vs liver A 0.99 <0.001
DECO Liver A vs blood 0.99 <0.001
Liver B vs blood 0.9 <0.001
Liver B vs liver A 0.92 <0.001
Control Liver A vs blood 0.96 <0.001
Liver B vs blood 0.96 <0.001
Liver B vs liver A 0.97 <0.001
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Equivalency emerged from the bivariate fit of 3HB levels
in A samples versus blood/B samples in diabetic
ketoacidosis cases is shown in Fig. 1a. Equivalency
emerged from the bivariate fit of 3HB levels in A samples
versus blood/B samples in nondiabetic cases presenting
decompositional changes (DECO) and in nondiabetic cases
without decompositional changes (control) is shown in
Fig. 1b. The regression line for every correlation described
angle bisector between the axes.
Discussion
The postmortem diagnosis of diabetes mellitus with fatal
complications, particularly ketoacidosis, requires the de-
termination of specific biochemical markers. Vitreous
glucose has been proposed by several authors as the
most appropriate laboratory parameter to estimate ante-
mortem blood glucose levels [12–16]. Other analyses
involving the determination of the glycosylation level
of some blood proteins [17–22] and ketone measure-
ment in body fluids [23–31] have also been indicated
to corroborate the hypotheses of constant antemortem
hyperglycemia and increased blood ketone concentra-
tions at the time of death, respectively.
Determination of ketone bodies in blood or alternative
biological fluids, along with measurements of other biochem-
ical parameters including vitreous glucose, urine adrenaline,
and postmortem serum hormones, proteins, and markers of
chronic alcohol consumption, has also been proposed in diag-
nosing alcoholic and starvation ketoacidosis as well as in
supporting the hypothesis of hypothermia as the cause of
death [10, 32–41].
The possibilities of establishing reliable diagnoses of
diabetic ketoacidosis by using biochemical investigations
can be extremely compromised when vitreous and blood
are unavailable during autopsy or advanced putrefactive
changes are present [42].
These limitations, however, may be drastically re-
duced if ketone measurements in the postmortem setting
can be performed in biological fluids other than blood
with equally reliable results [25, 26, 32, 35, 38, 39].
The need to identify alternative biological samples is
therefore paramount. These should be collectable even
when autopsies are performed on bodies presenting ad-
vanced decompositional changes and, above all, the
measured compounds should normally be present and
not increase with the onset of putrefaction.
Decompositional phenomena may markedly influence
toxicological and biochemical results because they induce
modifications in drug concentrations and may be responsi-
ble for molecule degradation. Additionally, putrefaction
may lead to the production of numerous lower molecular
weight compounds, drugs, or new substances by way of
artefact, which may affect the way in which case results
are interpreted [3, 43–46].
Iten and Meier [10] analyzed the relationship between
blood 3HB concentrations and the interval after death in a
series of medicolegal autopsies and did not observe any
statistical increase in postmortem blood 3HB levels. These
findings led to the conclusion that decompositional changes
were not associated with 3HB production and that blood
3HB levels in decomposed bodies could be considered an
appropriate biochemical parameter in the estimation of 3HB
concentrations at the time of death. Similar results were
obtained in two former studies, in which we investigated
Table 3 The linear function of 3HB levels in A samples versus B
samples and A samples versus blood in the three studied groups (in
parentheses standard error of intercept and slope)
Group Linear function R-square
DB liver A=−0.099 (0.565)+1.084 (0.051)×liver B 0.99
liver A=−1.127 (0.93)+0.983 (0.07)×blood 0.97
DECO liver A=−0.006 (0.016)+1.1 (0.112)×liver B 0.84
liver A=0.001 (0.005)+0.931 (0.036)×blood 0.97
Control liver A=0.0059 (0.006)+0.968 (0.053)×liver B 0.95
liver A=−0.0025 (0.009)+0.984 (0.0568)×blood 0.91
DB diabetic ketoacidosis, DECO nondiabetic cases presenting mode-
rate to severe decompositional changes, Control nondiabetic cases
without decompositional changes
+ d bl d DB + d li B DBan , oo - ; an , ver - X and - -, blood-DECO;  and , blood-Control,
X and - -, liver B-DECO;  and , liver B-Control
Fig. 1 Bivariate fit of 3HB
levels in A samples versus
blood/B samples in diabetic
ketoacidosis cases (DB) (a) and
in nondiabetic cases presenting
decompositional changes
(DECO) and in nondiabetic
cases without decompositional
changes (control) (b)
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blood 3HB levels in a series of medicolegal autopsies that
included bodies with decompositional changes [40, 47].
Kadiš et al. [39] had already postulated that 3HB does not
increase after death but, at most, may decrease due to
spontaneous molecule degradation.
Besides decompositional changes, other situations fre-
quently encountered in the forensic setting may force the
pathologist to deal with biological fluid insufficiency or
unavailability during autopsy or to collect biological sam-
ples of poor quality for toxicological and biochemical pur-
poses. Indeed, only small amounts of blood may be sampled
during infant autopsy and specimens are often missing
completely in severely damaged victims [48]. In these situ-
ations, the collection of alternative biological samples that
can be reliably analyzed and whose results can be faithfully
exploited to produce pertinent data is of utmost importance.
This is especially crucial when faced with pathological
processes, such as hypothermia, diabetic, alcoholic, and
starvation ketoacidosis, which may be characterized exclu-
sively by biochemical changes and limited (or absent) mor-
phological findings [49].
The liver has been deemed the primary solid tissue of use
in postmortem toxicology with the xenobiotic analysis
resulting from this tissue often complementing blood toxi-
cology data. Furthermore, the liver has the advantage of
being the main metabolic organ, allowing sufficient quanti-
ties of tissue to be collected during autopsy for analyses.
Liver samples are therefore the specimen of choice should
blood prove unavailable due to massive blood loss, fire
victims, or advanced decompositional changes. Liver sam-
ples can additionally be readily homogenized. Though the
liver is relatively unaffected by postmortem redistribution or
postmortem diffusion compared with blood, xenobiotic con-
centrations in the lobe proximal to the stomach and small
intestine may artificially increase due to postmortem diffu-
sion in cases of oral drug overdose. Therefore, use of tissue
from the deep part of the right lobe is preferred for toxico-
logical purposes [50–52].
In this study, we aimed to evaluate 3HB levels in liver
samples obtained from medicolegal autopsies including
cases of diabetic ketoacidosis fatalities and bodies
presenting decompositional changes. Our goal was to char-
acterize 3HB concentrations in liver homogenates and com-
pare them with peripheral (or cardiac) blood 3HB levels in
order to evaluate the usefulness of 3HB determination in
liver samples to objectify the metabolic disturbances that
can potentially cause or contribute to death.
The results of our study indicate that 3HB concentrations in
liver homogenates correlate well with blood values in all exam-
ined groups, thus allowing diabetic ketoacidosis to be diagnosed.
Additionally, in nondiabetic decomposed bodies and
nondiabetic individuals without decompositional changes,
3HB concentrations in both blood and liver samples were
within clinical blood reference values, suggesting that
decompositional changes are not associated with increased
blood 3HB levels. This observation concurs with the conclu-
sions of two former studies that focused on the interpretation of
postmortem blood 3HB levels in decomposed bodies [10, 39].
Lastly, according to the results of our analysis,
decompositional changes do not seem to be associated with
increases in 3HB liver concentrations.
Though further studies are required to confirm these pre-
liminary observations, our data suggest that 3HB can be
reliably measured in liver homogenates when blood is
unavailable during autopsy or when priority in using limited
amounts of blood must be given to toxicological investiga-
tions. Liver homogenates can be considered appropriate, al-
ternative, biological samples for 3HB determination when
blood, vitreous, urine, pericardial, and cerebrospinal fluids
cannot be collected during autopsy and biochemical investi-
gations could prove useful in evaluating the metabolic distur-
bances that may have potentially led or contributed to death.
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